Xeris Biopharma Holdings, Inc. received approval from the U.S. FDA for Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome for whom surgery is not an option or has not been curative.   Endogenous Cushing’s syndrome (CS) is a rare, serious and potentially lethal endocrine disease caused by chronic elevated cortisol exposure – often the result of a benign tumor of the pituitary gland. Nearly 40% of prescription-treated CS patients...